Defects in the ryanodine receptor (RYR1) gene are associated with malignant hyperthermia (MH), an autosomal dominant disorder of skeletal muscle and one of the main causes of death resulting from anaesthesia. Susceptibility to MH (MHS) is determined by the level of tension generated in an in vitro muscle contracture test (IVCT) in response to caffeine and halothane. To date, mutation screening of the RYRI gene in MH families has led to the identification of eight mutations. We describe here the identification of a novel mutation, Arg552Trp, in the RYR1 gene, which is clearly linked to the MHS phenotype in a large, well characterised Irish pedigree. Considering that the RYRI protein functions as a tetramer, correlation of the IVCT with the affected and unaffected haplotypes was performed on the pedigree to investigate if the normal RYR1 allele in affected subjects contributes to the variation in the IVCT. The results show that the normal RYR1 allele is unlikely to play a role in IVCT variation.
Malignant hyperthermia (MH) is a potentially fatal, autosomal dominant disorder of skeletal muscle.' 2 MH is triggered in susceptible people by volatile anaesthetics and depolarising muscle relaxants and is characterised by a pattern of physiological responses consistent with anaesthetic induced abnormalities in muscle excitation-contraction coupling.' 3 Fulminant MH typically presents with hypercontracture, metabolic and respiratory acidosis, tachycardia, raised temperatures, and death, if not treated with the postsynaptic muscle relaxant, dantrolene.' 2 Many susceptible patients present with some, but not all, of the classical signs with variable intensity when exposed to agents known to induce the condition. Some known susceptible patients have had previous triggering anaesthetics without any complications.' The was performed as described previously.'3 The samples were run on a 6% polyacrylamide gel (acrylamide:N,N-methylenebisacrylamide = 99:1) (1) at room temperature, (2) at room temperature with 5% glycerol, and (3) at 4°C with 5% glycerol.
CLONING AND SEQUENCING
For sequencing of DNA, PCR products were end filled using the Klenow fragment and cloned into the SmaI site of the commercial vector pTZ18r (Pharmacia Biotech, Sweden). Dideoxy sequencing reactions were performed using universal forward and reverse primers. Eight clones of each sample were sequenced to distinguish actual base pair changes from changes that may be incorporated as a result of PCR artefacts. 
Results
The CK1 family presented (fig 1) is one of the largest and best characterised Irish MH families ascertained to date. Of the 21 people tested for MH susceptibility within this pedigree, seven (subjects 5, 6, 8, 15, 16, 17 , and 24) were tested before the establishment of the standarised European Malignant Hyperthermia Group protocol. The protocol used in Cork for testing the subjects before the standardisation of the IVCT in 1984 is essentially identical to the standardised protocol except that in some cases only one muscle strip from each person was tested and, in addition to the standard halothane and caffeine concentrations, tensions generated at one to three additional concentrations were also recorded for some of the strips. In previous mutation screening efforts, no RYR1 mutation was identified in this pedigree despite perform- In order to check for the presence of the C1654T missense mutation in the multiexon RYR1 gene in genomic DNA samples, it was necessary to design PCR primers that would allow amplification of the mutated region from genomic DNA. This was achieved by selecting PCR primers that closely flank the mutation. Using the primers 1624f (21mer) and 1755r (1) Markers :  D1 9S1 91  RYR1  G591A  C1 654T  A1 668G  T2286C  C3456T  T8586C  A9182G  D19S190 (3) (21mer) it was possible to amplify a 237 bp genomic fragment encompassing the C1654T mutation (fig 2A) . The amplified fragment was 86 bp larger than anticipated from the cDNA sequence, indicating the presence of an intron. Sequencing of the amplified 1624-1755 bp fragment of genomic DNA showed an intron at nucleotide position 1674 in the RYRI gene (fig 2A) . To establish whether the C1654T missense mutation was present in the normal population, genomic DNA of 200 normal chromosomes were examined for the presence of the mutation by checking the appropriate amplified products for the loss of a Sau3a restriction site. None displayed the candidate mutation. The mutation was also absent in 97 additional unrelated MHS and four unrelated CCD patients indicating that this is a rare mutation. Sequence analysis showed that the mutation occurs on a RYRI allele bearing the polymorphism A1668G. In order to determine if this polymorphism was associated with the C 1654T mutation, the heterozygosity frequency of A1668G in 132 chromosomes was determined using SSCP and found to be 0.71 for allele A1668 and 0.29 for allele G1 668. The C1654T mutation was not detected in any of these samples indicating that the C 1654T mutation is a newly occurring mutation.
Segregation analysis of the C1654T mutation was performed in the family and showed that the mutation cosegregated precisely with the MHS phenotype in the family (figs 1 and 2B (table 1) . Examination of the concentration of halothane required to reach the threshold value of 0.2 g was 1% for haplotype h and ranged from 0.5% to 1.5% for haplotype e. The concentration of caffeine required to reach the threshold value ranged from 1 mmol/l to 2 mmol/l for haplotype e and 0.5 mmol/l to 2 mmol/l for haplotype h. Thus despite the fact that all of the MHS subjects had the same mutation, significant variation was observed in the tensions generated in the IVCT. Furthermore, there was no correlation between the tensions generated with halothane versus those generated with caffeine. Indeed, subject 17 had one of the lowest responses to caffeine and one of the highest responses to halothane in the IVCT (table 1) .
Interestingly, all of the affected subjects reached the threshold value of 0.2 g tension at or below 1.5% halothane and no MHE phenotype was observed in the family. This may indicate that the Arg552Trp mutation has high penetrance with respect to the IVCT phenotyping.
Discussion
In an effort to identify new mutations in the RYR1 gene causing MH, SSCP analysis was completed on the entire 15.5 kb RYR1 gene from a MHS affected member of a large, well characterised Irish MH pedigree. Sequencing of a unique aberrant SSCP showed the novel RYR1 mutation, C1 654T, which segregated precisely with the MHS phenotype in the pedigree. This mutation is likely to have arisen from the deamination of a 5-methyl-C residue at the CpG sequence present at nucleotide position 1654 in the normal RYR1 gene. Analysis of the RYRI gene from 97 unrelated MHS patients showed that this mutation was absent, indicating that the C1 654T mutation is a rare mutation. The chances of the mutation being a coincidental polymorphism are remote as it is clearly linked to the MHS phenotype in the pedigree, has not been detected in 200 normal chromsomes tested, and is conserved across species and RYR1 isoforms.
The evidence to date indicates that MH and CCD mutations in the RYR1 gene make the calcium release channel more sensitive to activating concentrations of halothane, caffeine, and other stimulators of channel opening. 33 34 The molecular mechanism by which RYRI mutations cause this hypersensitive gating is unknown. In mutant channels, enhanced rates of Ca"+ release from the sarcoplasmic reticulum during anaesthesia could result in the internal Ca2" concentrations reaching a threshold level where triggering of Ca2" induced Ca2' release through the RYR1 channel occurred continuously. Such a mechanism would explain the sustained muscle contraction and the sustained glycolytic and aerobic metabolism seen in MH. Mutations in the RYRI gene making the calcium release channel more sensitive to low concentrations ofhalothane and caffeine would also explain the physiological response observed in muscle samples from susceptible patients in the IVCT. The addition of caffeine or halothane (or ryanodine) to a MHS sample would lead to an increased amount of Ca2" released through the channels, producing a corresponding increase in tension by comparison with a MHN sample.
The results presented show that there is considerable variation in the IVCT caffeine and halothane responses in the different affected subjects in the pedigree. The basis for variability within the IVCT is unclear. Large pedigrees such as the one presented here, which are well characterised at the IVCT and genetic level, offer an opportunity to identify factors contributing to the IVCT variability. Since the RYR1 calcium release channel functions as a homotetramer3 and the IVCT tensions are linked to the levels of calcium released during the test, we postulated that the normal allele of the RYR1 gene might play a role in the variation in the IVCT response in MHS subjects within a pedigree. If the normal RYR1 allele is responsible for the variation one would expect that people sharing a particular normal allele and a given mutant allele might have a similar response. However, the analysis here showed that the normal RYR1 allele does not appear to play a role in IVCT variation, since the six subjects carrying the RYR1 mutant allele and the unaffected h haplotype exhibited wide variation in their IVCT responses. Similarly, the five affected subjects bearing unaffected haplotype e also exhibited wide variation in their IVCT responses.
Understanding the basis of variation in the IVCT response is an important issue in MH diagnosis. The reason for this is that some apparently normal subjects exhibit a MHE reaction in the absence of a segregating MHS mutation, while some susceptible subjects carrying known mutations can exhibit a marginal MHE response in the IVCT.' The MHE phenotype is poorly understood and until such time as the basis of MHE is understood, its existence diminishes the prospect of a genetic means for MHN diagnosis in MH pedigrees.
The work presented shows that the normal RYR1 allele is not likely to be a significant contributing factor to variation in the IVCT. However, even though a large, well characterised pedigree was used here, the total numbers investigated are small and it is possible that the unaffected RYRI haplotype contributes to IVCT variation in pedigrees carrying other RYR1 mutations. Alternatively, other good candidates that might play a role in IVCT variation would be those proteins that interact with the RYR1 homotetramer, such as the FIBP 12 protein35 3 and the dihydropyridine receptor.37
The sarcoplasmic reticulum Ca2" ATPases which are responsible for the rapid uptake of Ca21 from the myoplasm into the sarcoplasmic reticulum would also merit investigation. Finally, the contribution of experimental factors to the variation of the IVCT has not been assessed in detail and it remains to be determined what contribution such factors make to IVCT variation. 
